{{Rsnum
|rsid=10947089
|Gene=FLOT1
|Chromosome=6
|position=30742358
|Orientation=plus
|GMAF=0.06107
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=FLOT1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 95.3 | 4.7 | 0.0
| HCB | 84.4 | 13.3 | 2.2
| JPT | 97.7 | 2.3 | 0.0
| YRI | 65.1 | 33.3 | 1.6
| ASW | 0.0 | 0.0 | 0.0
| CHB | 84.4 | 13.3 | 2.2
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs10947089
|Name_s=3' UTR c.-14-155C>T
|Gene_s=FLOT1, IER3
|Feature=
|Evidence=PubMed ID:19837266
|Annotation=Risk or phenotype-associated allele, tested allele: unspecified; multi-ethnic minor allele is G per dbSNP Phenotype: In 114 cases and 414 controls (n = 528), univariate analysis of disease association showed OR = 0.18 for heterozygote (no carriers of homozygote variant in controls), versus homozygous wild type, in ALL, with P(trend) OR = 1.23, p = 0.61 using an additive model. Study size: 528. Study population/ethnicity: Childhood acute lymphoblastic leukemia (<=14 years) and healthy newborn controls (1988 to 1999) from South Wales in the United Kingdom. Significance metric(s): Non-significant finding p = 0.61. Type of association: CO.
|Drugs=
|Drug Classes=
|Diseases=Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA165110235
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs10947089
|overall_frequency_n=6
|overall_frequency_d=128
|overall_frequency=0.046875
|n_genomes=6
|n_genomes_annotated=0
|n_haplomes=6
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}